Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

ASH Highlights

Meeting Highlights

ASH Highlights

Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis

Meeting Highlights

ASH Highlights

Teclistamab, a BCMA x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1 Study Updates

Meeting Highlights

ASH Highlights

Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

Meeting Highlights

ASH Highlights

Novel Therapeutic Strategies with P-BCMA-101 CAR T-Cells in Patients with RRMM: Phase 1/2 Study Results

Meeting Highlights

ASH Highlights

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with RRMM

Meeting Highlights

ASH Highlights

ANCHOR: Melflufen + Dexamethasone and Daratumumab or Bortezomib in RRMM Patients Refractory to an IMiD and/or Proteasome Inhibitor

Meeting Highlights

ASH Highlights

Systematic Review and Network Meta-Analysis of the Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-Refractory Multiple Myeloma

Meeting Highlights

ASH Highlights

APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

Meeting Highlights

ASH Highlights

BFCR4350A, a FcRH5 x CD3 T-Cell–Engaging Bispecific Antibody, in Patients with RRMM: Preliminary Clinical Activity and Safety

Meeting Highlights

ASH Highlights

Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM

Page 3 of 7
Results 21 - 30 of 70